

## Curriculum vitae and publications – Jens Peter Gøtze

---

Born January 11, 1969, in Elsinore, Denmark. Married, two children.

### **Education and university degrees**

1987: 'Studentereksamen', Holte Gymnasium, Denmark.  
 1997: MD, University of Copenhagen, Denmark.  
 2005: DMSc, University of Copenhagen (ISBN 87-990801-0-9).  
 2008: Medical Specialist in clinical biochemistry.  
 2012: Adjunct professor in cardiovascular endocrinology, University of Aarhus, Denmark.  
 2016: Visiting Scientist at the Mayo Clinic, Rochester, USA.

### **Employment**

1993 - 1995: Scholarship, The Danish Cancer Society.  
 1997 - 1998: Internship, Hvidovre Hospital, Denmark.  
 1998 - 1999: Introductory position, Department of Clinical Biochemistry, Rigshospitalet, Denmark.  
 1999 - 2000: Introductory position, Department of Medicine, Rigshospitalet, Denmark.  
 2000 - 2003: Research assistant, Rigshospitalet, Denmark.  
 2003 - 2005: Teaching position, Department of Clinical Biochemistry, Rigshospitalet, Denmark.  
 2005 - 2006: Senior resident, Department of Clinical Biochemistry, Rigshospitalet, Denmark.  
 2006 - 2007: Senior resident, Department of Clinical Biochemistry, Skåne University Hospital, Malmö, Sweden.  
 2007 - 2007: Senior resident, Department of Clinical Biochemistry, Rigshospitalet, Denmark.  
 2007 - 2008: Senior resident, Department of Clinical Biochemistry, Bispebjerg Hospital, Denmark.  
 2007 - 2009: Staff physician/fellow, Department of Clinical Biochemistry, Rigshospitalet, Denmark.  
 2007 - 2014: External associate professor, Department of Health Sciences, Copenhagen University, Denmark.  
 2009 -: Chief physician, Department of Clinical Biochemistry, Rigshospitalet, Denmark.  
 2013 -: Consultant in charge of research, Metropolitan University College, Copenhagen, Denmark.  
 2015 -: Chief physician in charge of education and training of junior doctors, Department of Clinical Biochemistry, Rigshospitalet, Denmark.

### **Scientific publications**

May 2017: 257 publications, including 164 original articles, 41 review articles and letters, 15 editorials, 9 book chapters, and 28 other publications. Of these, 56 publications as first author, 56 as last author, and 17 as single author. Citations 3100; average 12; H-index (Web of Science) = 26.

### **Management and administration**

As of 2009 chief physician in charge of the coagulation section, Department of Clinical Biochemistry, Rigshospitalet, Denmark. The lab provides its services to the eastern part of Denmark with highly specialized analyses for hemophilia disorders, and for thrombosis disorders on a regional scale, including genetic testing for rare thrombotic disorders. This activity presupposes a close cooperation with the clinical unit in charge of these disorders at Rigshospitalet. As of 2011 financial responsibility for the department's section for peptide research, consisting of three professors, one chief physician, postdocs, PhD students, MSc students, and laboratory technicians. Management training (management of employees, 1 year) via The Capital Region of Denmark, and research management training (0.5 years). Nominated for The Capital Region of Denmark Management Award in 2013.

### ***Teaching and education theory***

- Teacher of gross anatomy to medical students and students of dentistry at the University of Copenhagen (1994-1996).
- Teacher of anatomy at the rehabilitation center, Karlslunde, Denmark (1999-).
- Teacher of clinical biochemistry to medical students (1999-) and A-course participants (2006-).
- Pre-graduate teaching of medical students at the University of Copenhagen for professors at Department of Clinical Biochemistry (2009-) in subjects covering clinical endocrinology and thrombosis and hemostasis.
- Teacher at PhD courses in cardiology and clinical biochemistry at Aarhus and Copenhagen Universities, respectively (2009-).
- Course in teaching of adults (1 week).
- Teacher at seminar on research mediation, the Capital Region of Denmark (2015-).
- Main responsibility for annual PhD course in science presentation at the University of Copenhagen (2012-).

### ***Directorships***

- Member of the board of directors of the Øfeldt Center (2010-).
- Member of the board of directors of Warwara Larsens Fond (2016-).

### ***Research supervisor***

Currently supervisor for six PhD students, three future PhD students, two doctoral dissertations (DMSc), and two doctors (PhDs) working on doctoral theses. Have completed the "SUND Seminar on Responsible Conduct of Research" for PhD supervisors (2015).

- Supervisor – PhD student Bjarke Follin Larsen (2013-). Topic: Treatment with stem cells in clinical cardiology.
- Supervisor – PhD student Qasam Ghulam (2014-). Topic: The connection between thrombosis and biomarkers at aorta aneurisms.
- Supervisor – PhD student Dijana Terzic (2015-). Topic: Natriuretic peptides and hormones in the gastrointestinal tract.
- Supervisor – PhD student Christina Kjær (2015-). Topic: Molecular characterization of human epileptic tissue.
- Supervisor – PhD student Lasse Holst Hansen (2016-). Topic: Post-translational modification of natriuretic peptides.
- Supervisor – PhD student Rune Strandby (2016-). Topic: Natriuretic peptides as markers of fluid hemostasis during surgery.
- Supervisor – MDs in specialist training Anne Willerslev and Peter Dall Mark.
- Supervisor – future PhD student Kathrine Overgaard Foss Jensen.

Formerly supervisor on PhD theses and masters dissertations at Institute of Health Sciences at Copenhagen and Aarhus Universities:

- Supervisor – Søren Junge Nielsen (PhD defense 2008). Topic: C-type natriuretic peptide, methodology development, characterization of tissue expression, and proCNP as biomarker for prostate cancer. A total of six articles have been published with supervisor as last author.
- Supervisor – Maren Skau (PhD defense 2010). Topic: Natriuretic peptides in cerebrospinal fluid at idiopathic, elevated intra-cranial pressure. A total of one article has been published with supervisor as co-author.
- Supervisor – Birgitte Kousholt (PhD defense 2012). Topic: Natriuretic peptides in cardioprotection. A total of two articles have been published with supervisor as last author.

- Main supervisor – Julie Smith (PhD defense 2012). Topic: Natriuretic peptides in neonatology and congenital heart disease. A total of five articles have been published with main supervisor as last author on three articles.
- Supervisor – Ingrid Hunter (PhD defense 2013). Topic: Natriuretic peptides in lab animals and at heart disease. A total of three articles have been published with supervisor as last author, followed by seven subsequent articles.
- Main supervisor – Solvej Lippert (PhD defense 2014). Topic: C-type natriuretic peptide at urogenital disease, including prostate cancer. A total of three articles have been published with main supervisor as last author.
- Main supervisor – Annette Timm (master's thesis, defended 2013). Topic: New diagnostic possibilities at von Willebrand's Disease. A total of five articles have been published with main supervisor as last author on four articles.
- Main supervisor – Lasse Holst Hansen (master's thesis, defended 2014). Topic: Glycosylation in the heart with particular emphasis on natriuretic hormones. A total of two articles have been published with main supervisor as last author (ongoing process).
- Main supervisor – Dijana Terzic (master's thesis, defended 2015). Topic: The relation between insulin and ANP in the heart. A total of two articles and one book chapter have been published with more articles in preparation.
- Main supervisor – Kathrine Overgaard Foss Jensen (master's thesis, defended 2016). Topic: Analyses re. "novel" anticoagulants. One original article has been submitted.
- Supervisor for postdoc Jakob Albrethsen (2014 - 2016).
- Supervisor for postdoc Ewa Soltysinska (2014 - 2015).
- Supervisor for postdoc Nora Zois (2012 - 2016).
- Supervisor for postdoc Julie Smith (2014 - 2016).

Formerly supervisor for four scholarship students:

- Medical student Anders Hejmdal Poulsen (natriuretic peptides and cardiogenic shock).
- Medical student Jesper Madsen (natriuretic peptides and post-translational processing).
- Medical student Louise Honoré (purification of human N-terminal proBNP).
- Medical student Signe Eiland (gastrin at ventricular cancer).

Formerly supervisor for "forskningsårsstuderende", medical student Martin Frydland (chromogranin A at acute myocardial infarct). In addition supervisor on eight 'OSVAL 2' assignments (medical student Anders Hejmdal Poulsen, medical student Jesper Madsen, medical student Louise Honoré, medical student Casper Bang, medical student Martin Andersen, medical student Camilla Bardram Johnbeck, medical student Ida Willer, medical student Kirstine Pilgaard Lærum).

### **Scientific nominations**

- Nomination of Christina Christoffersen for 'Jakobinermedaljen' 2013.
- Nomination of Dijana Terzic for the 'Lab Technician of the Year' award 2015.
- Nomination of 'Øfeldt Centret' for 'Vanførefondens Forskerpris' 2016.
- Nomination of scientists for the Nobel Prize in medicine and physiology 2016 on invitation from the Assembly.

### **Awards**

- Winner of lecture competition for young cardiologists in Scandinavia (XIX Nordic Congress of Cardiology, Odense 2003; *Ugeskr Laeger* 2003;**165**:2923), and 2<sup>nd</sup> place at the Astrup competition (Nordic Congress in Clinical Chemistry, Malmø 2004; *Klinisk Kemi i Norden* 2004;**16**:8-12).
- Awarded the Christenson-Ceson scholarship (2006).
- Awarded 'Jakobinermedaljen' by 'Selskabet for Teoretisk og Anvendt Medicin' (2008).
- Awarded the Research Award of the Odd Fellow Order (2014).



### **Scientific opponent/assessor**

- Assessor on PhD thesis at the Institute of Health Sciences at the University of Copenhagen (Bachelor of Medicine Tue Christoffersen, March 2007).
- Opponent on health scientific doctor's thesis at Lund University, Sweden (Cecilia Oslakovic, June 2010).
- Assessor on lectorate at the medical research lab, Institute for Clinical Medicine, Health, Aarhus University (June 2012).
- Assessor on research professorship at Medical School, University of Otago, Christchurch, New Zealand (August 2012).
- Assessor on health scientific PhD thesis at University of Southern Denmark (MSc pharm Helene Skjøt-Arkil, April 2013).
- Assessor on health scientific doctoral thesis at University of Oslo, Norway (Bachelor of Medicine Erik Tandberg Askevold, July 2013).
- Assessor on PhD thesis at University of Otago, New Zealand (Mauthri J Siriwardena, August 2013).
- Assessor on bachelor project at Copenhagen University (Thomas D. Madsen, June 2015).
- Assessor on PhD thesis at University of Gent, Belgium (Nicky Van Der Vekens, Juni 2015).
- Assessor on PhD thesis at Copenhagen University (Signe Torøng, August 2015).
- Reviewer (n = 140) on manuscripts for international journals including *The Lancet*, *European Heart Journal*, *American Journal of Physiology*, *Clinical Chemistry*, *FASEB Journal*, *Journal of the American College of Cardiology*, *Circulation*, and *Circulation Research*.

### **Editor-functions, organization of meetings**

- Organizer of seminar on natriuretic peptides (Copenhagen 2002) and of the annual meeting of the Danish Society for Clinical Biochemistry (Copenhagen 2003). Co-editor on the members' magazine of the Danish Society for Clinical Biochemistry (2005 - 2007).
- Initiator and organizer of the "Båstad" seminar on cardiovascular endocrinology (2009 -).
- Initiator and organizer of "The Abildgaard Symposium 2010: Mammalian Cardiovascular Endocrinology". A co-operation between Rigshospitalet and KU-LIFE, Copenhagen.
- Chair of "The 19<sup>th</sup> International Symposium on Regulatory Peptides, Copenhagen, 2012.
- Member of *Nordic Hemophilia Council*, NCG (2008 -).
- Member of the Editorial Board: *Biomarkers in Medicine* (2009 -).
- Member of the Editorial Board: *Journal of Pediatric Biochemistry* (2009 -).
- Member of the Editorial Board: *Journal of Geriatric Cardiology* (2010 -).
- Member of the Editorial Board: *Journal of Biomarkers* (2012 -).
- Associate Editor: *Cardiovascular Endocrinology* (2012 -).
- Member of the Editorial Board: *Research Journal of Endocrinology and Metabolism* (2013 -).
- Member of the Editorial Board: *Peptides* (2014 - 2016).
- Member of the Editorial Board: *Frontiers in Cardiovascular Medicine* (2015 -).

### **Labor union activities**

- Employee representative for 2½ years for young doctors at Rigshospitalet. Completed training as employee representative (FAYL courses I+II).
- Appointed inspector of the diagnostic areas of specialization by the Danish Society for Clinical Biochemistry and trained by the Danish Health and Medicines Authority (2010-2017).

### **Courses/training**

Completed external courses on cardiologic issues and A-courses under the principal training in clinical biochemistry. Passed the FELASA C-course = independent permission for experiments on animals.

### **External grants during the last 8 years**

2008: 200,000 DKK from the Lundbeck Foundation.  
 2009: 500,000 DKK from the Lundbeck Foundation.  
 2009: 150,000 DKK from the P.A. Messerschmidt Foundation.  
 2009: 125,000 DKK from 'Eva og Henry Frænkels Mindefond'.  
 2010: General grant from 'Rigshospitalets forskningsråd' (3 x 300,000 DKK).  
 2010: 750,000 DKK from the Lundbeck Foundation.  
 2012: General grant from the Novo Nordisk Foundation (5 x 1,000,000 DKK).  
 2013: 30,000 DKK from 'Snedkermester Sophus Jacobsen og hustru Astrid Jacobsens Fond'.  
 2013: 1,463,000 DKK from The Capital Region of Denmark.  
 2014: 100,000 DKK from the Arvid Nilsson Foundation.  
 2014: 200,000 DKK from the Toyota Foundation.  
 2015: 300,000 DKK from The Centre of Diagnostic Investigations, Rigshospitalet (Co-financing of PhD stipend).  
 2015: 1,250,000 DKK from the international KFJ Prize (with the Mayo Clinic, USA).

### **Scientific collaborations**

- National collaborations with heads of research sections at own department and at Rigshospitalet in general (Professors Lars Køber, Jens Kastrup, and Jesper Hastrup Svendsen, and chief physician Finn Gustafsson). In addition collaborations with professor Jan Skov Jensen (Gentofte Hospital), professor Søren Møller (Hvidovre Hospital), professor Jørgen Jeppesen (Glostrup Hospital), professor Michael Hasenkam (Skejby Hospital), and professor Jan Fahrenkrug (Bispebjerg Hospital).
- International collaborations with professor Ulf Dahlström (Linköbing University Sweden), professor John Burnett Jr. (the Mayo Clinic, USA), and professors Fred Apple (Minnesota University, USA), Gary Baxter (Cardiff University, UK), Leo Dunkel (Oulu University, Finland), and Mark Richards (Otago University, New Zealand).

### **Research vision**

My vision is a consolidation of *cardiovascular endocrinology* as a cross-functional discipline which takes its starting point in innovative biochemical and molecular methods for relevant peptide systems. The work is based on biochemical methodology, experimental models for human heart disease, and final tests in clinical studies. The subject is per definition cross-functional and requires a close collaboration with basic scientists and clinicians. Overall, the target is to contribute to a new understanding of the endocrine connections between organs in human heart diseases, and of the possibilities for new diagnostic and therapeutic initiatives.

## ***Publications***

I. Original articles (164).....	8
II. Review articles and letters (41).....	20
III. Editorials (15) .....	23
IV. Textbook chapters (9).....	24
V. Other publications (17) .....	25
VI. Danish communications (11) .....	26
VII. Patent applications (2).....	27
VIII. Manuscripts submitted or in preparation.....	28

Total no. of publications: 257. Figures in brackets indicate no. of publications per category.  
Abstracts not included.

## I. Original articles (164)

1. **Gøtze JP**, Lindeskog P, Törnquist CSI. Effects of induction and age-dependent enzyme expression on lung bioavailability, metabolism, and DNA binding of urban air particulate-absorbed benzo[a]pyrene, 2-nitrofluorene, and 3-amino-1,4-dimethyl-5H-pyridol-(4,3)-indole. *Environ Health Perspect* 1994;**102** Suppl 4:147-156.
2. **Gøtze JP**, Rehfeld JF. Displaced chromatographic elution of gastrin-17 in normal human serum. *Scand J Clin Lab Invest* 1994;**54**:673-676.
3. Hansen CP, **Gøtze JP**, Stadil F, Rehfeld JF. Excretion of progastrin products in human urine. *Am J Physiol* 1999;**276**:G985-G992.
4. **Gøtze JP**, Jensen CH. Follow-up of volar plate interposition arthroplasty (Tupper) of the metacarpophalangeal joints in rheumatoid hands: Preliminary findings. *Scand J Plast Reconstr Surg Hand Surg* 2000;**34**:249-251.
5. Hansen CP, **Gøtze JP**, Stadil F, Rehfeld JF. The metabolism of gastrin-52 and gastrin-6 in pigs. *Am J Physiol Gastroentest Liver Physiol* 2000;**279**:G552-560.
6. **Gøtze JP**, Nielsen FC, Burcharth F, Rehfeld JF. Closing the gastrin loop in pancreatic carcinoma – coexpression of gastrin and its receptor in solid human pancreatic adenocarcinoma. *Cancer* 2000;**88**:2487-2494.
7. **Gøtze JP**, Thorsen S, Haunsø S. Erhvervet warfarinresistens hos en patient med mekanisk mitralklap. *Ugeskr Laeger* 2001;**163**:7075-7076.
8. **Gøtze JP**, Kastrup J, Pedersen F, Rehfeld JF. Quantification of Pro-B-Type Natriuretic Peptide and its products in Human plasma by use of an analysis independent of precursor processing. *Clin Chem* 2002;**48**:1035-1042.
9. Christoffersen C, **Gøtze JP**, Bartels ED, Larsen MO, Ribel U, Rehfeld JF, Rolin B, Nielsen LB. Chamber-dependent expression of brain natriuretic peptide and its mRNA in normal and diabetic pig heart. *Hypertension* 2002;**40**:54-60.
10. Konturek PC, Bielanski W, Konturek SJ, Hartwich A, Pierzhalski P, Duda A, Karczewska E, Marlicz M, Starzynska T, Lawniczak M, Darasz Z, **Gøtze JP**, Rehfeld JF, Hahn EG. Progastrin and cyclooxygenase-2 in colorectal cancer. *Dig Dis Sci* 2002;**47**:1984-1991.
11. **Gøtze JP**, Rehfeld JF. Impact of assay epitope specificity in gastrinoma diagnosis. *Clin Chem* 2003;**49**:333-334.
12. **Gøtze JP**, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Kastrup J, Nielsen LB. Increased cardiac BNP gene expression associated with myocardial ischemia. *FASEB J* 2003;**17**:1105-1107. Epub 2003 Apr 22 (10.1096/fj.02-0796fje).
13. Konturek SJ, Gonciarz M, Gonciarz Z, Bielanski W, Mazur W, Mularczyk A, Konturek PC, **Gøtze JP**, Rehfeld JF. Progastrin and its products from patients with chronic viral hepatitis and liver cirrhosis. *Scand J Gastroenterol*, 2003;**38**:643-647.
14. Christoffersen C, Bollano E, Lindegaard MLS, Bartels ED, **Gøtze JP**, Andersen CB, Nielsen LB. Cardiac lipid accumulation associated with diastolic dysfunction in obese mice. *Endocrinology* 2003;**144**:3483-3490.
15. Henriksen JH, **Gøtze JP**, Fuglsang S, Christensen E, Bendtsen F, Møller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in



patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. *Gut* 2003;**52**:1511-1517.

16. Konturek SJ, Konturek PC, Bielanski W, Karczewska E, Zuchowicz M, Hartwich A, Rehfeld JF, **Gøtze JP**, Hahn EG. Serum progastrin and its products, gastric acid secretion and serum pepsinogen I in gastric cancer. *Digestion* 2003;**68**:169-177.
17. **Gøtze JP**, Henriksen JH, Fuglsang S, Christensen E, Bendtsen F, Møller S. Cirrotisk kardiomyopati: øget cirkulerende pro-brain-natriuretisk peptid og brain-natriuretisk peptid ved cirrose. *Ugeskr Laeger* 2004;**166**:2999-3002 (parallelpublikation).
18. **Gøtze JP**, Videbæk R, Boesgaard S, Aldershvile J, Rehfeld JF, Carlsen J. Pro-brain natriuretic peptide as marker of cardiovascular or pulmonary causes of dyspnea in patients with terminal parenchymal lung disease. *J Heart Lung Transplant* 2004;**23**:80-87.
19. **Gøtze JP**, Wang Y, Rehfeld JF, Jørgensen E, Kastrup J. Coronary angiography transiently increases plasma pro-B-type natriuretic peptide. *Eur Heart J* 2004;**25**:759-764.
20. **Gøtze JP**, Gore A, Møller CH, Steinbrüchel DA, Rehfeld JF, Nielsen LB. Acute myocardial hypoxia increases BNP gene expression. *FASEB J* 2004;**18**:1928-1930. Epub 2004 Sept 22 (10.1096/fj.03-1336fje).
21. **Gøtze JP**, Rehfeld JF, Videbæk R, Friis-Hansen L, Kastrup J. B-type natriuretic peptide and its precursor in cardiac venous blood from failing hearts. *Eur J Heart Fail* 2005;**7**:69-74.
22. Wang YZ, **Gøtze JP**, Videbæk R, Rehfeld JF, Kastrup J. Increased circulating endothelins are not of cardiopulmonary origin in heart failure patients. *Scand J Clin Lab Invest* 2005;**65**:341-347.
23. **Gøtze JP**, Paloheimo LI, Linnala A, Sipponen P, Hansen CP, Rehfeld JF. Gastrin-17 specific antibodies are too specific for gastrinoma diagnosis but stain G-cells. *Scand J Gastroenterol* 2005;**40**:596-598.
24. Halse KG, Lindegaard MLS, **Gøtze JP**, Damm P, Mathiesen ER, Nielsen LB. Increased plasma pro-B-type natriuretic peptide in infants of women with type I diabetes. *Clin Chem* 2005;**51**:2296-2302.
25. Nielsen SJ, Rehfeld JF, Pedersen F, Kastrup J, Videbæk R, **Gøtze JP**. Measurement of pro-C-type natriuretic peptide in plasma. *Clin Chem* 2005;**51**:2173-2176.
26. **Gøtze JP**, Jensen G, Møller S, Bendtsen F, Rehfeld JF, Henriksen JH. BNP and N-terminal pro-BNP are both extracted in the normal kidney. *Eur J Clin Invest* 2006;**36**:8-15.
27. **Gøtze JP**, Hansen CP, Rehfeld JF. Antral content, secretion and peripheral metabolism of N-terminal progastrin fragments. *Regul Pept* 2006;**133**:47-53.
28. **Gøtze JP**, Rehfeld JF, Carlsen J, Videbæk R, Andersen CB, Boesgaard S, Friis-Hansen L. Apelin: A new plasma marker of cardiopulmonary disease. *Regul Pept* 2006;**133**:134-138.
29. Runge M, Hughes P, **Gøtze JP**, Petersen R, Steinbrüchel DA. Evaluation of myocardial metabolism with microdialysis after protection with cold blood- or crystalloid cardioplegia. A porcine model. *Scand Cardiovasc J* 2006;**40**:186-193.
30. **Gøtze JP**, Møgelvang R, Måge L, Scharling H, Schnohr P, Søgaard P, Rehfeld JF, Jensen JS. Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction. *Eur Heart J* 2006;**27**:3004-3010.

31. Hejmdal A, Boesgaard S, Lindholm MG, **Gøtze JP**. B-type natriuretic peptide and its molecular precursor in myocardial infarction complicated by cardiogenic shock. *J Card Fail* 2007;**13**:184-188.
32. Nybo M, Nielsen LB, Nielsen SJ, Lindegaard MLS, Damm P, Rehfeld JF, **Gøtze JP**. Discordant expression of pro-B-type and pro-C-type natriuretic peptide in newborn infants of mothers with type 1 diabetes. *Regul Pept* 2007;**141**:135-139.
33. Damgaard M, **Gøtze JP**, Norsk P, Gadsbøll N. Altered sodium intake affects plasma concentrations of BNP but not proBNP in healthy subjects and patients with compensated heart failure. *Eur Heart J* 2007;**28**:2726-2731.
34. Ripa RS, Wang Y, **Gøtze JP**, Jørgensen E, Johnsen HE, Kastrup J. Circulating angiogenic cytokines and stem cells in patients with severe chronic ischemic heart disease — Indicators of myocardial ischemic burden? *Int J Cardiol* 2007;**120**:181-187.
35. Alehagen U, **Gøtze JP**, Dahlström U. Reference intervals and decision limits for B-type natriuretic peptide (BNP) and its precursor (Nt-proBNP) in the elderly. *Clin Chim Acta* 2007;**382**:8-14.
36. Nybo M, Benn M, Møgelvang R, Jensen JS, Schnohr P, Rehfeld JF, **Gøtze JP**. Impact of hemoglobin on plasma pro-B-type natriuretic peptide concentrations in the general population. *Clin Chem* 2007;**53**:1921-1927.
37. Møgelvang R, **Gøtze JP**, Schnohr P, Lange P, Sogaard P, Rehfeld JF, Jensen JS. Discriminating between cardiac and pulmonary dysfunction in the general population with dyspnea by plasma pro-B-type natriuretic peptide. *J Am Coll Cardiol* 2007;**50**:1694-1701.
38. Nielsen SJ, Rehfeld JF, **Gøtze JP**. Mismeasure of C-type natriuretic peptide. *Clin Chem* 2008;**54**:225-227.
39. Nielsen SJ, **Gøtze JP**, Jensen H, Rehfeld JF. ProCNP and CNP are expressed primarily in male genital organs. *Regul Pept* 2008;**146**:204-212.
40. Møller CH, Nørgaard MA, **Gøtze JP**, Andersen CB, Olsen VN, Steinbrüchel DA. Selective retrograde venous revascularization of the myocardium when PCI or CABG is impossible: investigation in a porcine model. *Heart Surg Forum* 2008;**11**:E99-104.
41. Friis-Hansen L, Sælsen L, Abildstrøm SZ, **Gøtze JP**, Hilsted LM. An algorithm for applying flagged Sysmex XE-2100 absolute neutrophil counts in clinical practice. *Eur J Haematol* 2008;**81**:140-153.
42. **Gøtze JP**, Dahlström U, Rehfeld JF, Alehagen U. Impact of epitope specificity and precursor maturation in pro-B-type natriuretic peptide measurement. *Clin Chem* 2008;**54**:1780-1787.
43. Christiansen MS, Iversen K, Larsen CT, **Gøtze JP**, Hommel E, Mølviig J, Pedersen BK, Magid E, Feldt-Rasmussen B. Increased urinary orosomucoid excretion: a proposed marker for inflammation and endothelial dysfunction in patients with type 2 diabetes. *Scand J Clin Lab Invest* 2009;**69**:272-281.
44. Poulsen TD, Andersen LW, Steinbrüchel D, **Gøtze JP**, Jørgensen OS, Olsen NV. Two large preoperative doses of erythropoietin do not reduce the systemic inflammatory response to cardiac surgery. *J Cardiothorac Vasc Anesth* 2009;**23**:316-323.
45. Nielsen SJ, Iversen P, Jensen H, Rehfeld JF, **Gøtze JP**. C-type natriuretic peptide in prostate cancer. *APMIS* 2009;**117**:60-67.

46. Møgelvang R, Søgaard P, Pedersen SA, Olsen NT, Marott JL, Schnohr P, **Gøtze JP**, Jensen JS. Cardiac dysfunction assessed by echocardiographic tissue Doppler imaging is an independent predictor of mortality in the general population. *Circulation* 2009;**119**:2679-2685.
47. Møgelvang R, **Gøtze JP**, Pedersen SA, Olsen NT, Marrot JL, Schnohr P, Søgaard P, Jensen JS. Preclinical systolic and diastolic dysfunction assessed by tissue doppler imaging is associated with elevated plasma pro-B-type natriuretic peptide concentrations. *J Card Fail* 2009;**15**:489-495.
48. Schou M, Alehagen U, **Gøtze JP**, Gustafsson F, Dahlström U. Effect of estimated glomerular filtration rate on plasma concentrations of B-type natriuretic peptides measured with multiple immunoassays in elderly individuals. *Heart* 2009;**95**:1514-1519.
49. Nilsson B, **Gøtze JP**, Chen X, Pehrson S, Svendsen JH. Increased NT-pro-B-type natriuretic peptide independently predicts outcome following catheter ablation of atrial fibrillation. *Scand J Clin Lab Invest* 2009;**69**:843-850.
50. Pecini R, Hammer-Jensen S, Dalsgaard M, **Gøtze JP**, Hassager C, Køber L. Determinants of exercise-induced increase of mitral regurgitation in patients with acute coronary syndromes. *Echocardiography* 2010;**27**:567-574.
51. **Gøtze JP**, Georg B, Jørgensen HL, Fahrenkrug J. Chamber-dependent circadian expression of cardiac natriuretic peptides. *Regul Pept* 2010;**160**:140-145.
52. Skau M, **Gøtze JP**, Rehfeld JF, Jensen R. Natriuretic pro-peptides in idiopathic intracranial hypertension. *Regul Pept* 2010;**164**:71-77.
53. Bonfils PK, Damgaard M, Taskiran M, **Gøtze JP**, Norsk P, Gadsbøll N. Impact of diuretic treatment and sodium intake on plasma volume in patients with compensated systolic heart failure. *Eur J Heart Fail* 2010;**12**:995-1001.
54. Bartels EM, Nielsen JM, Bisgaard LS, **Gøtze JP**, Nielsen LB. Decreased expression of natriuretic peptides associated with lipid accumulation in cardiac ventricle of obese mice. *Endocrinology* 2010;**151**:5218-5225.
55. Lippert SK, Rehfeld JF, **Gøtze JP**. Processing-independent analysis for pro-C-type natriuretic peptide. *J Immunol Methods* 2010;**362**:32-37.
56. Alehagen U, Dahlström U, Rehfeld JF, **Gøtze JP**. Prognostic assessment of elderly patients with symptoms of heart failure by combining high-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide measurements. *Clin Chem* 2010;**56**:1718-1724.
57. Mygind ND, Harutyunyan MJ, Mathiasen AB, Ripa RS, Thune JJ, **Gøtze JP**, Johansen JS, Kastrup J, The CLARICOR Trial Group. The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease. *Inflamm Res* 2011;**60**:281-287.
58. Harutjunjan MJ, Mathiasen AB, Winkel P, **Gøtze JP**, Hansen JF, Hildebrandt P, Jensen GB, Hilden J, Jespersen CM, Kjølner E, Kolmos, HJ, Gluud C, Kastrup J, CLARICOR Trial Group. High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial. *Scand J Clin Lab Invest* 2011;**71**:52-62.
59. Hermann TS, Dall CH, Christensen SB, **Gøtze JP**, Prescott E, Gustafsson F. Effect of high intensity exercise on peak oxygen uptake and endothelial function in long-term heart transplant recipients. *Am J Transplant* 2011;**11**:536-541.

60. Olsen NT, Sogaard P, Larsson HBW, **Gøtze JP**, Jons C, Mogelvang R, Nielsen OW, Fritz-Hansen T. Speckle-tracking echocardiography for predicting outcome in chronic aortic regurgitation during conservative management and after surgery. *JACC Cardiovasc Imaging* 2011;**4**:223-230.
61. Passino C, Franzino E, Giannoni A, Prontera C, **Gøtze JP**, Emdin M, Clerico A. B-type natriuretic peptide secretion following scuba diving. *Biomarkers Med* 2011;**5**:205-209.
62. Sennels HP, Jørgensen HL, Hansen AL, **Gøtze JP**, Fahrenkrug J. Diurnal variation of hematology parameters in healthy young males: The Bispebjerg study of diurnal variations. *Scand J Clin Lab Invest* 2011;**71**:532-541.
63. Rehfeld JF, Gingras MH, Bardram L, Hilsted L, **Gøtze JP**, Poitras P. The Zollinger-Ellison syndrome and mismeasurement of gastrin. *Gastroenterology* 2011;**140**:1444-1453.
64. Hunter I, Alehagen U, Dahlström U, Rehfeld JF, Crimmins DL, **Gøtze JP**. N-terminal pro-atrial natriuretic peptide measurement in plasma suggests covalent modification. *Clin Chem* 2011;**57**:1327-1330.
65. Hunter I, Rehfeld JF, **Gøtze JP**. Measurement of the total proANP product in mammals by processing independent analysis. *J Immunol Methods* 2011;**370**:104-110.
66. Mathiasen AB, Harutyunyan MJ, Jørgensen E, Helqvist S, Ripa R, **Gøtze JP**, Johansen JS, Kastrup J. Plasma YKL-40 in relation to the degree of coronary artery disease in patients with stable ischemic heart disease. *Scand J Clin Lab Invest* 2011;**71**:439-447.
67. Alehagen U, Dahlström U, Rehfeld JF, **Gøtze JP**. Association of copeptin and N-terminal proBNP concentrations to risk of cardiovascular death in elderly patients with symptoms of heart failure. *JAMA* 2011;**305**:2088-2095.
68. Carlsen CM, Bay M, Kirk V, **Gøtze JP**, Køber L, Nielsen OW. Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study. *Eur J Heart Fail* 2012;**14**:240-247.
69. Sennels HP, Jørgensen HL, **Gøtze JP**, Fahrenkrug J. Rhythmic 24-hour variations of frequently used clinical biochemical parameters in healthy young males – The Bispebjerg study of diurnal variations. *Scand J Clin Lab invest* 2012;**72**:287-295.
70. Husby S, Lind B, **Gøtze JP**. Practical use of natriuretic peptide measurement: questionnaire results from general practitioners and cardiologists. *Biomark Med* 2012;**6**:13-18.
71. Carlsen CM, Bay M, Kirk V, **Gøtze JP**, Køber L, Nielsen OW. Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study. *Eur J Heart Fail* 2012;**14**:240-247.
72. Smith J, **Gøtze JP**, Sondergaard L, Kjaergaard J, Iversen KK, Vejlstrop NG, Hassager C, Andersen CB. Myocardial hypertrophy after pulmonary regurgitation and valve implantation in pigs. *Int J Cardiol* 2012;**159**:29-33.
73. Kilpeläinen L, Ivaska KK, Kuiri-Hänninen T, Väänänen HK, Rehfeld JF, **Gøtze JP**, Sankilampi U, Dunkel L. Urinary osteocalcin and serum pro-C-type natriuretic peptide predict linear catch-up growth in infants. *J Bone Miner Res* 2012;**27**:1528-1535.

74. Balling L, Kistorp C, Schou M, Egstrup M, Gustafsson I, **Gøtze JP**, Hildebrandt P, Gustafsson F. Plasma copeptin levels and prediction of outcome in heart failure outpatients: relation to hyponatremia and loop diuretic doses. *J Card Fail* 2012;**18**:351-358.
75. Egstrup M, Schou M, Tuxen CD, Kistorp CN, Hildebrandt PR, Gustafsson F, Faber J, **Gøtze JP**, Gustafsson I. Prediction of outcome by highly sensitive troponin-T in outpatients with chronic systolic left ventricular heart failure. *Am J Cardiol* 2012;**110**:552-557.
76. Munk M, Memon AA, **Gøtze JP**, Nielsen LB, Nexø E, Sørensen BS. Hypoxia changes the expression of the epidermal growth factor (EGF) system in human hearts and in cultured cardiomyocytes. *PLoS One* 2012;**7**:e40243.
77. Kousholt BS, Larsen JKR, Bisgaard L, Burnett JC Jr, Hasenkam JM, **Gøtze JP**. Natriuretic peptide infusion reduces myocardial injury during acute ischemia/reperfusion. *Cardiovasc Endocrinol* 2012;**1**:4-12.
78. Terzic D, Johansson-Fällgren AS, Ragnarsson O, **Gøtze JP**, Hammarsten O. Evaluation of a sensitive copeptin assay for clinical measurement. *Open Clin Chem J* 2012;**5**:21-26.
79. Møller S, Mortensen C, Bendtsen F, Jensen LT, **Gøtze JP**, Madsen JL. Cardiac sympathetic imaging with *mIBG* in cirrhosis and portal hypertension: relation to autonomic and cardiac function. *Am J Physiol Gastrointest Liver Physiol* 2012;**303**:G1228-1235.
80. **Gøtze JP**, Jørgensen HL, Sennels HP, Fahrenkrug J. Diurnal plasma concentrations of natriuretic propeptides in healthy young males. *Clin Chem* 2012;**58**:789-792.
81. Alehagen U, Dahlström U, Carstensen J, Rehfeld JF, **Gøtze JP**. Combined measurement of copeptin, high-sensitivity troponin T, and N-terminal proBNP improves the identification of patients at risk of cardiovascular death. *Cardiovascular Endocrinology* 2012;**1**:68-73.
82. Alehagen U, Dahlström U, Rehfeld JF, **Gøtze JP**. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure. *J Card Fail* 2013;**19**:31-39.
83. Smith J, Halse KG, Damm P, Lindegaard MLS, Amer-Wählin I, Hertel S, Johansen M, Mathiesen ER, Nielsen LB, **Gøtze JP**. Copeptin and MR-proADM in umbilical cord plasma reflect perinatal stress in neonates born to mothers with diabetes and MR-proANP reflects maternal diabetes. *Biomark Med* 2013;**7**:139-146.
84. Mygind ND, Iversen K, Køber L, **Gøtze JP**, Nielsen H, Boesgaard S, Bay M, Johansen J, Nielsen OW, Kirk V, Kastrup J. The inflammatory biomarker YKL-40 at admission is a strong predictor of overall mortality. *J Intern Med* 2013;**273**:205-216.
85. Iversen K, Køber L, **Gøtze JP**, Dalsgaard M, Nielsen H, Boesgaard S, Bay M, Kirk V, Nielsen OW. Troponin T is a strong marker of mortality in hospitalized patients. *Int J Cardiol* 2013;**168**:818-824.
86. Harutyunyan M, **Gøtze JP**, Winkel P, Johansen JS, Hansen JF, Jensen GB, Hilden J, Kjølner E, Kolmos HJ, Glud C, Kastrup J. Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: A prognostic study within the CLARICOR trial. *Immunobiology* 2013;**218**:945-951.
87. **Gøtze JP**, Eiland S, Svendsen LB, Vainer B, Hannibal J, Rehfeld JF. Characterization of gastrins and their receptor in solid human gastric adenocarcinomas. *Scand J Gastroenterol* 2013;**48**:688-695.

88. Smith J, Christoffersen C, Nørgaard LM, Olsen LH, Vejstrup NG, Andersen CB, **Gøtze JP**. Cardiac natriuretic peptide gene expression and plasma concentrations during the first 72 hours of life in pigs. *Endocrinology* 2013;**154**:1864-1872.
89. **Gøtze JP**. Plasma proANP decreases after meal intake. *Clin Chem* 2013;**59**:1270-1271.
90. Asferg CL, Nielsen SJ, Andersen UB, Linneberg A, Møller DV, Hedley PL, Christiansen M, **Gøtze JP**, Esler M, Jeppesen JL. Relative atrial natriuretic peptide deficiency and inadequate renin and angiotensin II suppression in obese hypertensive men. *Hypertension* 2013;**62**:147-153.
91. Halse KG, Lindegaard LS, Amer-Wahlin I, Hertel S, Johansen M, Nielsen LB, **Gøtze JP**, Mathiesen ER, Damm P. Cardiac function in offspring of women with diabetes using fetal ECG, umbilical cord blood pro-BNP, and neonatal interventricular septal thickness. *Cardiovasc Endocrinol* 2013;**2**:55-59.
92. Bonfils PK, Taskiran M, Damgaard M, **Gøtze JP**, Floyd AK, Funch-Jensen P, Kristiansen VB, Gadsbøll N. The influence of high versus low sodium intake on blood pressure and haemodynamics in patients with morbid obesity. *J Hypertens* 2013;**31**:2220-2229.
93. Krogh J, **Gøtze JP**, Jørgensen MB, Kristensen LØ, Kistorp C, Nordentoft M. Copeptin during rest and exercise in major depression. *J Affect Disord* 2013;**151**:284-290.
94. Frydland M, Kousholt B, Larsen JR, Burnett JC Jr, Hilsted L, Hasenkam JM, **Gøtze JP**. Increased N-terminal CgA in circulation associated with cardiac reperfusion in pigs. *Biomark Med* 2013;**7**:959-967.
95. Cirera S, Moesgaard SG, Zois NE, Ravn N, **Gøtze JP**, Cremer SE, Teerlink T, Leifsson PS, Hønge JL, Hasenkam MJ, Olsen LH. Plasma proANP and SDMA and microRNAs are associated with chronic mitral regurgitation in a pig model. *Endocr Connect* 2013;**2**:161-171.
96. Lauridsen BK, Iversen K, Hunter I, Bay M, Kirk V, Nielsen OW, Nielsen H, Boesgaard S, Køber L, **Gøtze JP**. ProANP plasma measurement predicts all-cause mortality in acutely hospitalised patients: a cohort study. *BMJ Open* 2013;**3**:e003288.
97. Christensen HM, Schou M, **Gøtze JP**, Faber J, Frystyk J, Flyvbjerg A, Kistorp C. Body mass index in chronic heart failure: association with biomarkers of neurohormonal activation, inflammation and endothelial dysfunction. *BMC Cardiovasc Disord* 2013;**13**:80.
98. Bosselmann H, Egstrup M, Rossing K, Gustafsson I, Gustafsson F, Tønder N, Kistorp CN, **Gøtze JP**, Schou M. Prognostic significance of cardiovascular biomarkers and renal dysfunction in outpatients with systolic heart failure: A long term follow-up study. *Int J Cardiol* 2013;**170**:202-207.
99. Wiese S, Mortensen C, **Gøtze JP**, Christensen E, Andersen O, Bendtsen F, Møller S. Cardiac and proinflammatory markers predict prognosis in cirrhosis. *Liver Int* 2014;**34**:e19-30.
100. Lyngbæk S, Winkel P, **Gøtze JP**, Kastrup J, Gluud C, Kolmos HJ, Kjølner E, Jensen GB, Hansen JF, Hildebrandt P, Hilden J, the CLARICOR Trial Group. Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide. *Eur J Prev Cardiol* 2014;**21**:1275-1284.
101. Rank UC, Hovinga JK, Taleghani MM, Lämmle B, **Gøtze JP**, Nielsen OJ. Congenital thrombotic thrombocytopenic purpura caused by new compound heterozygous mutations of the *ADAMTS13* gene. *Eur J Haematol* 2014;**92**:168-171.

102. Ruwald MH, **Gøtze JP**, Bech J, Nielsen OW, Madsen BK, Nielsen LB, Mouridsen M, Ruwald A-CH, Madsen JK, Pedersen S. NT-proBNP independently predicts long-term mortality in patients admitted for coronary angiography. *Angiology*, 2014;65:31-36.
103. Asferg C, Nielsen SJ, Andersen UB, Linneberg A, Møller DV, Hedley PL, Christiansen M, **Gøtze JP**, Jeppesen J. Metabolic rather than body composition measurements are associated with lower serum natriuretic peptide concentrations in normal weight and obese men. *Am J Hypertens* 2014;27:620-627.
104. Gustafsson G, Gude E, Sigurdardottir V, Aukrust P, Solbu D, **Gøtze JP**, Gullestad L. Plasma NGAL and glomerular filtration rate in cardiac transplant recipients treated with standard or reduced calcineurin inhibitor levels. *Biomark Med* 2014;8:239-245.
105. Rehfeld JF, Bardram L, Hilsted L, **Gøtze JP**. An evaluation of chromogranin A versus gastrin and progastrin in gastrinoma diagnosis and control. *Biomark Med* 2014;8:571-580.
106. Hansen LH, Smith J, **Gøtze JP**. Cardiac C-type natriuretic peptide gene expression and plasma concentrations in neonatal piglets. *Regul Pept* 2014;188:66-69.
107. Skov J, Holst JJ, **Gøtze JP**, Frøkiær J, Christiansen JS. Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males. *Endocr Connect* 2014;3:11-16.
108. Dalsgaard M, Iversen K, Kjaergaard J, Grande P, **Gøtze JP**, Clemmensen P, Hassager C. Short-term hemodynamic effect of angiotensin-converting enzyme inhibition in patients with severe aortic stenosis. A placebo-controlled, randomized study. *Am Heart J* 2014;167:226-234.
109. Kimer N, **Gøtze JP**, Bendtsen F, Møller S. New vasoactive peptides in cirrhosis: organ extraction and relation to the vasodilatory state. *Eur J Clin Invest* 2014;44:441-452.
110. **Gøtze JP**, Hilsted L, Rehfeld JF, Alehagen U. Plasma chromogranin A is a marker of death in elderly patients presenting with symptoms of heart failure. *Endocr Connect* 2014;3:47-56.
111. Asferg CL, Andersen UB, Linneberg A, **Gøtze JP**, Jeppesen JL. Copeptin, a surrogate marker for arginine vasopressin secretion, is associated with higher glucose and insulin concentrations but not higher blood pressure in obese men. *Diabet Med* 2014;31:728-732.
112. Bosselmann H, Tonder N, Sölétormos G, Rossing K, Iversen K, **Gøtze JP**, Gustafsson F, Schou M. Influence of renal impairment on myocardial function in outpatients with systolic heart failure: an echocardiographic and cardiac biomarker study. *Int J Cardiol* 2014;177:942-948.
113. Timm A, Fahrenkrug J, Jørgensen HL, Sennels HP, **Gøtze JP**. Diurnal variation of von Willebrand factor in plasma: the Bispebjerg study of diurnal variations. *Eur J Haematol* 2014;93:48-53.
114. Christensen DL, Espino D, Infante-Ramírez R, Brage S, Terzic D, **Gøtze JP**, Kjaergaard J. Normalization of elevated cardiac, kidney, and hemolysis plasma markers within 48 h in Mexican Tarahumara runners following a 78 km race at moderate altitude. *Am J Hum Biol* 2014;26:836-43.
115. Kistorp C, Bliddal H, **Gøtze JP**, Christensen R, Faber J. Cardiac natriuretic peptides in plasma increase after dietary induced weight loss in obesity. *BMC Obesity* 2014;1:24. Online publication.

116. Iversen K, **Gøtze JP**, Dalsgaard M, Nielsen H, Boesgaard S, Bay M, Kirk V, Nielsen OW, Køber LV. Risk stratification in emergency patients by copeptin. *BMC Medicine* 2014;**12**:80.
117. Andersen MJ, Ersbøll M, Bro-Jeppesen J, Møller JE, Hassager C, Køber L, Borlaug BA, **Gøtze JP**, Gustafsson F. Relationships between biomarkers and left ventricular filling pressures at rest and during exercise in patients after myocardial infarction. *J Cardiac Failure* 2014;**20**:959-67.
118. Balling L, Gustafsson F, **Gøtze JP**, Dalsgaard M, Nielsen H, Boesgaard S, Bay M, Kirk V, Nielsen OW, Køber L, Iversen K. Hyponatremia at hospital admission is a predictor of overall mortality. *J Intern Med* 2015;**45**:195-202.
119. Timm A, Hillarp A, Philips M, **Gøtze JP**. Comparison of automated von Willebrand factor activity assays. *Thrombosis Res* 2015;**135**:684-691.
120. Lippert SK, Iversen P, Brasso K, **Gøtze JP**. C-type natriuretic peptide and its precursor: Potential markers in human prostate cancer. *Biomarkers Med* 2015;**9**:319-326.
121. **Gøtze JP**, Johnsen AH, Johnbeck CB, Rehfeld JF. Cardiomyocyte expression and cell-specific processing of procholecystokinin. *J Biol Chem* 2015;**290**:6837-6843.
122. Holmager P, Schou M, Egstrup M, Gustafsson I, **Gøtze JP**, Gustafsson F, Klausen TW, Faber J, Kistorp K. The influence of diabetes mellitus on mid-regional pro-adrenomedullin concentrations and prognostic value in heart failure patients. *J Cardiac Failure* 2015;**21**:250-257.
123. Joergensen C, Tarnow L, **Gøtze JP**, Rossing P. Vitamin D analogue therapy, cardiovascular risk and kidney function in type 1 diabetic patients with diabetic nephropathy – a randomized trial. *Diabetic Med* 2015;**32**:343-352.
124. Kjeld T, Jattu T, Nielsen HB, **Gøtze JP**, Secher NH, Olsen NV. Release of EPO, S100B and neuron-specific enolase after breath-hold in free divers. *Scand J Med Sci Sports* 2015;**25**:253-257.
125. Lindberg S, Jensen JS, Pedersen SH, Galatius S, **Gøtze JP**, Møgelvang R. ProANP improves prediction of mortality and cardiovascular events in patients with STEMI. *Eur J Prev Cardiol* 2015;**22**:693-700.
126. Bonfils PK, Taskiran M, Damgaard M, **Gøtze JP**, Floyd AK, Funch-Jensen P, Kristiansen VB, Støckel M, Bouchelouche PN, Gadsbøll N. Roux-en-Y gastric bypass alleviates hypertension and is associated with an increase in mid-regional pro-atrial natriuretic peptide in morbid obese patients. *J Hypertens* 2015;**33**:1215-1225.
127. Von Scholten BJI, Lajer M, **Gøtze JP**, Persson F, Rossing P. Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. *Diabet Med* 2015;**32**:343-352.
128. Theilade S, Hansen TW, **Gøtze JP**, Rossing P. Increased Plasma concentrations of midregional proatrial natriuretic peptide is associated with risk of cardiorenal dysfunction in type 1 diabetes. *Am J Hypertens* 2015;**28**:772-779.
129. Von Scholten BJ, Hansen TW, **Gøtze JP**, Persson F, Rossing P. Glucagon-like peptide 1 receptor antagonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. *J Diabetes Complications* 2015;**29**:670-674.



130. Schou M, Bosselmann H, Gaborit F, Iversen K, **Gøtze JP**, Soletomas G, Rasmussen, J, Kistorp C, Kober L, Gustafsson F, Tonder N. Iron Deficiency: Prevalence and relation to cardiovascular biomarkers in heart failure outpatients. *Int J Cardiol* 2015;**195**:143-148.
131. Mylin AK, **Gøtze JP**, Heickendorff L, Ahlberg L, Dahl IM, Abildgaard N, Gimsing P. N-terminal pro-C-type natriuretic peptide in serum associated with bone destruction in patients with multiple myeloma. *Biomark Med* 2015;**9**:679-689.
132. Smith J, Fahrenkrug J, Jørgensen HL, Christoffersen C, **Gøtze JP**. Diurnal gene expression of lipolytic natriuretic peptide receptors in white adipose tissue. *Endocr Connect* 2015;**4**:206-214.
133. Siebenmann C, Cathomen A, Hug M, Keiser S, Lundby AK, Hilty MP, **Gøtze JP**, Rasmussen P, Lundby C. Hemoglobin mass and intravascular volume kinetics during and after exposure to 3,454-m altitude. *J Appl Physiol* 2015;**119**:1194-1201.
134. Goharian TS, Gimsing AN, **Gøtze JP**, Faber J, Andersen LB, Grøntved A, Jeppesen JL. Mid-regional pro-atrial natriuretic peptide and blood pressure in adolescents: Effect of gender and pubertal stage. *Blood Press* 2015;**24**:347-352.
135. Gaborit F, Bosselmann H, Tønder N, Iversen K, Kümler T, Kistorp C, Sölétormos G, **Gøtze JP**, Schou M. Association between left ventricular global longitudinal strain and natriuretic peptides in outpatients with chronic systolic heart failure. *BMC Cardiovasc Disord* 2015;**15**:92.doi:10.1186/s12872-015-0063-8.
136. Lindberg S, Jensen JS, Hoffmann S, Pedersen SH, Iversen AZ, Galatius S, Frystyk J, Flyvbjerg A, **Gøtze JP**, Bjerre M, Mogelvang R. Interplay between adiponectin, pro-atrial natriuretic peptide and prognosis in patients with ST-Segment Elevation Myocardial Infarction. *Am J Cardiol* 2015;**116**:1340-1345.
137. Guo S, **Gøtze JP**, Jeppesen JL, Burnett Jr JC, Olesen J, Jansen-Olesen I, Ashina M. Effect of natriuretic peptides on cerebral artery blood flow in healthy volunteers. *Peptides* 2015;**74**:33-42.
138. Fabiansen C, Lykke M, Hother A-L, Koch J, Nielsen OB, Hunter I, **Gøtze JP**, Friis H, Thymann T. Cardiac dysfunction in a porcine model of pediatric malnutrition. *Plos One* 2015;**10**:e0140472 (1-16).
139. Van Der Vekens N, Hunter I, Timm A, Decloedt A, De Clercq D, Deprez P, **Gøtze JP**, van Loon G. Total plasma proANP increases atrial dilatation in horses. *Vet Rec* 2015;**177**:624. doi: 10.1136/vr.103316.
140. Wiese S, Timm A, Nielsen LB, **Gøtze JP**, Bendtsen F, Møller S. Plasma ADAMTS-13 protein is not associated with portal hypertension or hemodynamic changes in patients with cirrhosis. *Dig Liver Dis* 2016;**48**:404-408.
141. Rasmussen KC, Højskov M, Ruhnau B, Salling L, Pedersen T, **Gøtze JP**, Secher NH. Plasma pro-atrial natriuretic peptide to indicate fluid balance during cystectomy: a prospective observational study. *BMJ Open* 2016;**6**:e010323.
142. Skov J, Pedersen M, Holst JJ, Madsen B, **Gøtze JP**, Rittig S, Jonassen T, Frøkiær J, Dejgaard A, Christiansen JS. Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial. *Diabetes Obes Metab* 2016;**18**:581-589.
143. **Gøtze JP**, Rehfeld JF, Alehagen U. Cholecystokinin in plasma predicts cardiovascular mortality in elderly females. *Int J Cardiol* 2016;**209**:37-41.

144. Gaborit FS, Bosselmann H, Kistorp C, Iversen K, Kumler T, Gustafsson F, **Gøtze JP**, Sölétormos G, Tønder N, Schou M. Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure. *BMC Cardiovasc Disord* 2016;**16**:117.
145. Montero D, Rauber S, **Gøtze JP**, Lundby C. Reduction in central venous pressure enhances erythropoietin synthesis: role of volume-regulating hormones. *Acta Physiol* 2016;**218**:89-97.
146. Vedel AG, Holmgaard F, Rasmussen LS, Paulson OB, Thomsen C, Danielsen ER, Langkilde A, **Gøtze JP**, Lange T, Ravn HB, Nilsson JC. Perfusion Pressure Cerebral Infarct (PPCI) trial - the importance of mean arterial pressure during cardiopulmonary bypass to prevent cerebral complications after cardiac surgery: study protocol for a randomised controlled trial. *Trials* 2016;**17**:247.
147. Jung MH, **Gøtze JP**, Boesgaard S, Sander K, Gustafsson F. Neurohormonal activation and exercise tolerance in patients supported with a continuous-flow left ventricular assist device. *Int J Cardiol* 2016;**220**:196-200.
148. Ghulam QM, Bredahl KK, Gram JB, Löhn L, **Gøtze JP**, Sillesen HH, Eiberg J. Von Willebrand factor and prekallikrein in plasma are associated with thrombus volume in abdominal aortic aneurysms. *Vasc Endovascular Surg* 2016;**50**:391-397.
149. Vestergaard KR, Jespersen CB, Arnadottir A, Sölétormos G, Schou M, Steffensen R, **Gøtze JP**, Kjølner E, Iversen KK. Prevalence and significance of troponin elevations in patients without acute coronary disease. *Int J Cardiol* 2016;**222**:819-825.
150. Asferg CL, Andersen UB, Linneberg A, Hedley PL, Christiansen M, **Gøtze JP**, Jeppesen JL. Serum proatrial natriuretic peptide does not increase with higher systolic blood pressure in obese men. *Heart* 2017;**103**:154-158.
151. Plesner LL, Schoos MM, Dalsgaard M, **Gøtze JP**, Kjølner E, Vestbo J, Iversen K. Iron deficiency in COPD associates with increased pulmonary artery pressure estimated by Echocardiography. *Heart Lung Circ* 2017;**26**:101-104.
152. Saenger AK, Rodriguez-Fraga O, Ler R, Ordonez-Llanos J, Jaffe AS, **Gøtze JP**, Apple FS. Specificity of B-type natriuretic peptide assays: Cross-reactivity with different BNP, NT-proBNP, and proBNP Peptides. *Clin Chem* 2017;**63**:351-358.
153. Strandby RB, Ambrus R, Secher NH, **Gøtze JP**, Achiam MP, Svendsen LB. Plasma pro-atrial natriuretic peptide to estimate fluid balance during open and robot-assisted esophagectomy: a prospective observational study. *BMC Anesthesiol* 2017;**17**:20.
154. Sørensen H, Thomsen JH, Meyer AS, Terzic D, Hilsted L, Kjærgaard J, **Gøtze JP**, Barbosa TC, Secher NH. Phenylephrine increases near-infrared spectroscopy determined muscle oxygenation in men. *J Clin Monit Comput* 2016;in press.
155. Ambrus R, Svendsen LB, Secher NH, **Gøtze JP**, Rünitz K, Frederiksen HJ, Achiam MP. Severe postoperative complications may be related to mesenteric traction syndrome during open esophagectomy. *Scand J Surg*, in press.
156. Bejder J, Andersen AB, **Gøtze JP**, Aachmann-Andersen NJ, Nordsborg NB. Plasma volume reduction and biomarker fluctuations in high-level athletes after an increased training load. *Scand J Med Sci Sports*, in press.
157. Sonne DP, Terzic D, Knop FK, **Gøtze JP**. Postprandial plasma concentrations of proANP in patients with type 2 diabetes and healthy controls. *Clin Chem*, in press.

158. **Gøtze JP**, Hansen CP, Rehfeld JF. Acute effects of N-terminal progastrin fragments on gastric acid secretion in man. *Physiol Reports* 2017;**5**:e13164.
159. Goharian TS, **Gøtze JP**, Faber J, Andersen LB, Grøntved A, Jeppesen JL. Associations of Pro-Atrial Natriuretic Peptide with Components of the Metabolic Syndrome in Adolescents and Young Adults from the General Population. *Am J Hypertens Am J Hypertens* 2017;**30**:561-568.
160. Zois NE, Terzic D, Færch K, Plomgaard P, Hansen JS, Rossing P, **Gøtze JP**. Effect of pancreatic hormones on pro-atrial natriuretic peptide in humans. *EBioMedicine* 2017;**17**:88-94.
161. Montero D, Breenfeldt-Andersen A, Overholzer L, Haier T, **Gøtze JP**, Meinild-Lundby AK, Lundby C. Erythropoiesis with endurance training: dynamics and mechanisms. *Am J Physiol*, in press.
162. Hansen LH, Darkner S, Svendsen JH, Henningsen K, Pehrson S, Chen X, Vakhrushev SY, Schjoldager KT, **Gøtze JP**. Chromogranin A in the mammalian heart: Expression without secretion. *Biomarkers Med*, in press.
163. Hagdrup C, Park-Hansen J, Svendsen JH, **Gøtze JP**, Holme S, Carranza C, Nilsson B, Steinbrüchel D, Irmukhamedov, Dominguez H. MR-proANP rises during exercise even after surgical closure of the left atrial appendage: A substudy of the Laacs study. *J Cardiol Vasc Med*, in press.
164. Dall PM, Hunter I, Terzic D, **Gøtze JP**. Processing-independent proANP measurement for low concentrations in plasma: Reference intervals and effect of body mass index and plasma glucose. *Clin Chem Lab Med*, in press.

## II. Review articles and letters (41)

1. Rehfeld JF, Bardram L, Bundgaard JR, Friis-Hansen L, **Gøtze JP**, Hilsted L, Johnsen AH, Lüttichau HR, Nielsen FC, Paloheimo L, Pedersen K, Rourke IJ, van Solinge WW, Thorup JU. Expression and growth effects of gastrin and cholecystokinin peptides in neuroendocrine tumors and common carcinomas. *Falk Symposium No. 77: Gastrointestinal tract and endocrine system* (Klüwer Academic Publications, Lancaster, UK, 1995; pp. 379-405).
2. **Gøtze JP**, Kastrup J. Plasma pro-brain natriuretic peptides are strong biochemical markers in clinical cardiology. *Scand J Clin Lab Invest Suppl* 2001;234:47-51.
3. Rehfeld JF, **Gøtze JP**. The posttranslational phase of gene expression: new possibilities in molecular diagnosis. *Curr Mol Med* 2003;3:25-38.
4. Rehfeld JF, Bundgaard JR, **Gøtze JP**, Friis-Hansen L, Hilsted L, Johnsen AH. Progastrin, gastrins and bioactivity. Proceedings of the 11<sup>th</sup> International Conference on Ulcer Research, Dubrovnik, Croatia, September 15-20, 2003.
5. Rehfeld JF, Bundgaard JR, Friis-Hansen L, **Gøtze JP**. On the tissue-specific processing of procholecystokinin in the brain and gut – a short review. *J Physiol Pharmacol* 2003;54 Suppl 4:73-79.
6. Nielsen SJ, **Gøtze JP**, Raymond IE, Grønning BA, Kirk V, Bay M, Hildebrandt PR, Aldershvile J. De natriuretiske hjertehormoner. Klinisk anvendelse ved hjertesvigt. *Ugeskr Laeger* 2004;166:248-253.
7. Rehfeld JF, Bundgaard JR, **Gøtze JP**, Friis-Hansen L, Hilsted L, Johnsen AH. Naming progastrin-derived peptides. *Regul Pept* 2004;120:177-183.
8. **Gøtze JP**. ProBNP-derived peptides in cardiac disease. *Scand J Clin Lab Invest* 2004;64:497-510.
9. **Gøtze JP**. Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. *Clin Chem* 2004;50:1503-1510.
10. Friis-Hansen L, **Gøtze JP**, Kastrup J. Forgiftning med betablokkere og calciumantagonister. To kardiologiske problemer med endokrinologiske løsninger? *Ugeskr Laeger* 2004;166:3483-3487.
11. **Gøtze JP**, Rehfeld JF. Cardiac processing of natriuretic peptides in heart failure. *Clin Chem* 2004;50:2467-2468.
12. Nielsen LB, **Gøtze JP**. Letter regarding article by Bibbins-Domingo et al, "B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study". (Measurement of BNP versus proBNP in patients with coronary artery disease.) *Circulation* 2005;111:15-16.
13. Rehfeld JF, **Gøtze JP**. Gastrin vaccination against gastrointestinal and pancreatic cancer. *Scand J Gastroenterol* 2006;41:122-123.
14. **Gøtze JP**, Friis-Hansen L, Rehfeld JF, Nilsson B, Svendsen JH. Atrial secretion of B-type natriuretic peptide. *Eur Heart J* 2006;27:1648-1650.
15. Rehfeld JF, Friis-Hansen L, **Gøtze JP**, Hansen TvO. The biology of cholecystokinin and gastrin peptides. *Curr Top Med Chem* 2007;7:1154-1165.

16. **Gøtze JP**, Hillarp A, Lindblom A, Björk P, Strandberg K, Nielsen LB. Ny markør ved trombotisk trombocytopenisk purpura. *Ugeskr Laeger* 2008;**170**:2446-2449.
17. **Gøtze JP**, Lindblom A, Björk P, Nielsen LB, Strandberg K, Manea M, Hillarp A. ADAMTS13 – aktör och markör vid trombotisk mikroangiopati. *Läkartidningen* 2008;**105**:1092-1095.
18. Christoffersen C, Lethagen S, **Gøtze JP**. Heparininduceret trombocytopeni. *Ugeskr Laeger* 2009;**171**:612-615.
19. Smith J, **Gøtze JP**, Andersen CB, Vejlstrup N. Practical application of natriuretic peptides in paediatric cardiology. *Cardiol Young* 2010;**20**:353-363.
20. Veien KT, Jensen JK, Hildebrandt P, **Gøtze JP**, Nielsen OW, Køber L. Natriuretiske peptider som hjertemarkører I klinisk praksis. *Ugeskr Laeger* 2010;**172**:2111-2116.
21. Lippert SK, **Gøtze JP**. C-type natriuretic-derived peptides as biomarkers in human disease. *Biomark Med* 2010;**4**:631-639.
22. **Gøtze JP**, Johnsen AH, Rehfeld JF. Letter regarding article by Siriwardena M et al.: B-type natriuretic peptide signal peptide circulates in human blood: evaluation as a potential biomarker of cardiac ischemia. *Circulation* 2011;**123**:e232.
23. Rehfeld JF, Friis-Hansen L, **Gøtze JP**, Hilsted L, Nielsen FC. Diagnostik af neuroendokrine tumorer I mave-tarm-kanalen. *Ugeskr Laeger* 2010;**172**:2957-2960.
24. Crimmins DL, **Gøtze JP**. In vitro molecular structure of N-terminal B-type natriuretic peptide: monomer or oligomer? *Clin Chem* 2011;**57**:924-926.
25. **Gøtze JP**, Hunter I, Lippert SK, Bardram L, Rehfeld JF. Processing-independent analysis of peptide hormones and prohormones in plasma. *Front Biosci (Landmark Ed.)* 2012;**17**:1804-1815.
26. **Gøtze JP**. B-type natriuretic peptide: From post-translational processing to clinical measurement. *Clin Chem* 2012;**58**:83-91.
27. Rehfeld JF, Bardram L, Hilsted, L, Poitras P, **Gøtze JP**. Pitfalls in diagnostic gastrin measurements. *Clin Chem* 2012;**58**:831-836.
28. **Gøtze JP**, Hunter I, Smith J, Hasenkam JM. Pigs in space. *Cardiovasc Endocrinol* 2013;**2**:4-5.
29. **Gøtze JP**, Alehagen U, Flyvbjerg A, Rehfeld JF. Making sense of chromogranin A in heart disease. *Lancet Diabetes Endocrinol* 2013;**1**:7-8.
30. Bergen M, **Gøtze JP**. On the nature of depression: cardiovascular light for a shady condition. *Cardiovasc Endocrinol* 2013;**2**:38-39.
31. Van Der Vekens N, Hunter I, **Gøtze JP**, Decloedt A, De Clercq D, Van Loon G. Human and equine cardiovascular endocrinology: beware to compare. *Cardiovasc Endocrinol* 2013;**2**:67-76.
32. **Gøtze JP**, Alehagen U, Flyvbjerg A, Rehfeld JF. Chromogranin A as a biomarker in cardiovascular disease. *Biomarkers Med* 2014;**8**:133-140.
33. Hunter I, Terzic D, Zois NE, Olsen LH, **Gøtze JP**. Pig models for the human heart failure syndrome. *Cardiovasc Endocrinol* 2014;**3**:15-18.

34. Okholm C, **Gøtze JP**, Svendsen LB, Achiam MP. Inflammatory response in laparoscopic vs. open surgery for gastric cancer. *Scand J Gastroenterol* 2014;**49**:1027-1034.
35. Zois NE, Bartels ED, Hunter I, Kousholt BS, Olsen LH, **Gøtze JP**. Natriuretic peptides in cardiometabolic regulation and disease. *Nat Rev Cardiol* 2014;**11**:403-412.
36. Jespersen CHB, Vestergaard KR, Schou M, Teisner B, **Gøtze JP**, Iversen K. Pregnancy-associated plasma protein-A and the vulnerable plaque. *Biomark Med* 2014;**8**:1033-1047.
37. Guo S, Barringer F, Zois NE, **Gøtze JP**, Ashina M. Natriuretic peptides and cerebral hemodynamics. *Regul Pept* 2014;**193**:15-23.
38. Albrethsen J, **Gøtze JP**, Johnsen AH. Mining the granule proteome: a potential source of endocrine biomarkers. *Biomark Med* 2015;**9**:259-265.
39. **Gøtze JP**, Hansen LH, Terzic D, Zois NE, Albrethsen J, Timm A, Smith J, Soltysinska E, Lippert SK, Hunter I. Atrial natriuretic peptides in plasma. *Clin Chim Acta* 2015;**443**:25-28.
40. **Gøtze JP**, Rehfeld JF. Scientists Should Be Writing: Three reasons why authorship matters, even—perhaps especially—to established scholars. *The Scientist*, online publication, April 7, 2015.
41. Rehfeld JF, Hansen JS, Sonne DP, **Gøtze JP**. Biomarkers and immunoassay kits: a matter of growing concern. *Biomark Med* 2015;**9**:623-624.

### III. Editorials (15)

1. **Gøtze JP**, Kastrup J, Rehfeld JF. The paradox of increased natriuretic hormones in congestive heart failure patients: Does the endocrine heart also fail in heart failure? *Eur Heart J* 2003;**24**:1471-1472.
2. **Gøtze JP**, Videbæk R. More hormones spilt in heart failure: linking renal sympathetic activation to clinical outcome. *Eur Heart J* 2005;**26**:861-862. (10-1093/eurheartj/ehi220).
3. **Gøtze JP**. Coronary artery disease, heart failure, and cardiac natriuretic peptides in the middle. *Eur Heart J* 2005;**26**:2603-2604.
4. Christoffersen C, Hunter I, Jensen AL, **Gøtze JP**. Diabetes and the endocrine heart. *Eur Heart J* 2007;**28**:2427-2429.
5. **Gøtze JP**. Markers of activated coagulation in acute coronary syndromes. *J Am Coll Cardiol* 2008;**51**:2430-2431.
6. **Gøtze JP**, Rehfeld JF. Peptide hormones and their prohormones as biomarkers. *Biomarkers Med* 2009;**3**:335-338.
7. Hunter I, **Gøtze JP**. Next generation natriuretic peptide measurement. *Adv Clin Chem* 2012;**58**:45-48.
8. **Gøtze JP**. Defining cardiovascular endocrinology. *Cardiovasc Endocrinol* 2012;**1**:2-3.
9. **Gøtze JP**, Køber L. Genotype versus phenotype in cardiology: just a new coat of paint? *Biomarkers Med* 2013;**7**:501-503.
10. **Gøtze JP**, Krentz A. Animal models. *Cardiovasc Endocrinol* 2014;**3**:1.
11. **Gøtze JP**, Albrethsen J. Adropin: A new regulatory peptide in cardiovascular endocrinology. *Regul Pept* 2014;**190-191**:41-42.
12. **Gøtze JP**, Rehfeld JF. The men who stare at science. *Cardiovasc Endocrinol* 2015;**4**:117-118.
13. **Gøtze JP**, Rehfeld JF. Antibodies make analyses make answers. *Biomark Med* 2016;**10**:447.
14. **Gøtze JP**, Zois NE. Cardiac natriuretic peptides in plasma: from prediction to precision medicine. *Lancet Diabetes Endocrinol* 2016;**4**:803-805.
15. **Gøtze JP**, Sonne DP. Diabetes and its lack of causal biomarkers. *Biomark Med* 2016;**10**:1121-1123.

#### IV. Textbook chapters (9)

1. Rehfeld JF, **Gøtze JP**. The post-translational phase of gene expression in tumor diagnosis. M.A. Hayat (Ed): Handbook of immunohistochemistry and *in situ* hybridization of human carcinomas (volume 4). *Elsevier Academic Press USA* 2006:23-32.
2. **Gøtze JP**. Biosynthesis of cardiac natriuretic peptides. D. Richter & H. Tiedge (Eds): Cellular Peptide Hormone Synthesis and Secretory Pathways. *Results Probl Cell Differ* 2010;**50**:97-120 (*Springer Press*).
3. Rehfeld JF, **Gøtze JP**. Gastrin. Handbook of Biologically Active Peptides (2nd edition). Kastin AJ (Ed), *Academic Press* 2013:519-523.
4. Apple FS, **Gøtze JP**, Jaffe AS. Cardiac function. Tietz textbook of clinical chemistry and molecular diagnosis (5th edition). *Elsevier Saunders* 2012:1457-1522.
5. Apple FS, **Gøtze JP**, Jaffe AS. Cardiovascular disease. Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics (seventh edition). *Elsevier Saunders* 2014:632-650.
6. Terzic D, **Gøtze JP**. Copeptin and the heart failure syndrome. *UNI-MED Verlag AG* 2014;62-69.
7. Rehfeld JF, **Gøtze JP**. Forskning på klinisk biokemisk afdeling, Rigshospitalet 1954-2014 (ISBN 978-87-990619-1-4).
8. Apple FS, **Gøtze JP**, Jaffe AS. Cardiac function. Tietz textbook of clinical chemistry and molecular diagnosis (6th edition). *Elsevier Saunders* 2015, in press.
9. De Bold AF, Burnett Jr JC, **Gøtze JP**. Natriuretic peptides. Endocrinology: Principles of endocrinology and hormone action. *Springer press*, in press.



## V. Other publications (17)

1. Friis-Hansen L, **Gøtze JP**, Philip J. Graviditetskomplikationer og trombofili. *Ugeskr Laeger* 1999;**161**:5034.
2. Rehfeld JF, **Gøtze JP**. Barretts metaplasi og øsofaguskræft. *Ugeskr Laeger* 2003;**165**:2498.
3. **Gøtze JP**, Friis-Hansen L, Thorsen S, Rehfeld JF. Langtidsprofylakse efter venøs tromboembolisk sygdom. *Ugeskr Laeger* 2003;**165**:2896-2897.
4. **Gøtze JP**, Rehfeld JF. Hjertereptider – basalt set. *Ugeskr Laeger* 2003;**165**:3324-3325.
5. **Gøtze JP**, Rehfeld JF. Hjertehormonologi. *Ugeskr Laeger* 2004;**166**:1109.
6. **Gøtze JP**. Hjertets egne hormoner. *Klinisk Biokemi i Norden* 2005;**17**:8-12.
7. Rehfeld JF, **Gøtze JP**. Galdesten som symptom på kolecystokininresistens. *Ugeskr Laeger* 2005;**167**:2658-2659.
8. **Gøtze JP**, Hansen SH, Johnsen AH. Tacrolimus i blod: Immunsuppresiva analyseret med LC-MS/MS. *DSKB-Nyt* 2006;**2**:26-27.
9. **Gøtze JP**, Svensson PJ. Trombosbehandlingens længd bør inte styras av D-dimer. *Läkartidningen* 2007;**104**:851.
10. **Gøtze JP**, Nielsen LB. Heparin-induceret immunbetinget trombocytopeni. *DSTH-Forum* 2007;**2**:16-17.
11. **Gøtze JP**, Carlsson M, Friis-Hansen L, Nybo M, Thornemo M, Karlman M, Karawajczyk M, Zelvute I, Janukonyte J, Hel M, Frøyshov B, Aldrimer M. The professional role in a clinical chemistry laboratory: Snapshots from a boat trip to Bornholm. *Klinisk Biokemi i Norden* 2007;**19**:22-31.
12. Hunter I, Jensen AL, Koch J, Bjørnvad C, Smith J, **Gøtze JP**. Det endokrine hjerte og biokemisk diagnostik af hjertesygdom. *Dansk Veterinærtidsskrift* 2008;**91**:8-12.
13. Rehfeld JF, Bardram L, **Gøtze JP**, Hilsted L. Gastrin som markør af gastrinomer: Et lærestykke om immunanalyse-kits. *Klinisk Biokemi i Norden* 2011;**3**:20-24.
14. Hammarsten O, **Gøtze JP**. Copeptin: A new peptide in clinical measurement. *Klinisk Biokemi i Norden* 2012;**1**:22-31.
15. Brødbæk K, **Gøtze JP**. Fatal blødningskomplikation hos patient med akut nyresvigt behandlet med dabigatran. *DSKB Nyt* 2013;**1**:16-18.
16. Afzal S, Philips M, **Gøtze JP**. Antikoagulation og biokemisk monitorering anno 2015. *Klinisk Biokemi i Norden* 2015;**3**:18-22.
17. Albrethsen J, **Gøtze JP**, Johnsen AH. Immuno-MALDI: En lovende metode til måling af peptider. *Klinisk Biokemi i Norden* 2016;**3**:16-19.

**VI. Danish communications (11)**

1. **Gøtze JP.** Jens F. Rehfelds 60-års-dag. *Ugeskr Læger* 2001;**163**:7291.
2. Siersbæk Hansen L, **Gøtze JP.** *Ældre og Sundhed* 2002;**1**:14-15.
3. **Gøtze JP.** Fra spire til sten. *DSKB Nyt* 2009;**1**:22-23.
4. **Gøtze JP.** Krudtugler på stoffer. *Information* 2013;**29**:18-19.
5. **Gøtze JP.** Pausegymnastik. *Information* 2013;**34**:16-17.
6. **Gøtze JP.** Jeppe på fedtbjergget. *Information* 2013;**38**:14-15.
7. **Gøtze JP.** Drømmen og det lykkelige menneske. *Berlingske Tidende* 2014;**33**:25.
8. **Gøtze JP.** At dække et behov, der ikke er der. Eller? *dBIO* 2015;**10**:27.
9. **Gøtze JP.** Sundhedstyranniet skader vores børn. *Information* 2015;**51**:16-17.
10. Ørnstrup L, Laursten AK, Christiansen L, Hansen H, **Gøtze JP.** Stille, små mirakler. *dBIO* 2016;**6-7**:22-23.
11. **Gøtze JP.** Lucky Choices: En bog om livet med forskning af Jens Christian Skou. *Ugeskr Læger* 2016;**25**:

## VII. Patent applications (2)

1. A processing-independent neuropeptide assay. Rehfeld JF, **Gøtze JP**. Published April 11, 2003 (WO03/087819).
2. Use of progastrin-derived peptides. Rehfeld JF, Bundgaard JR, **Gøtze JP**. Filed February 6, 2004 (PA 2004 00180).

### VIII. Manuscripts submitted or in preparation

1. **Gøtze JP**, Guo S, Kousholt MS, Bartels ED, Larsen JR, Hasenkam M, Burnett Jr J, Nielsen LB, Ashina M. Natriuretic peptides increase free fatty acids in circulation and augment cardiac triglyceride accumulation.
2. Bonfils PK, Taskiran M, Damgaard M, **Gøtze JP**, Floyd AK, Funch-Jensen P, Kristiansen V, Gadsbøll N. The influence of high versus low sodium intake on blood pressure and hemodynamics in patients with morbid obesity.
3. Olsen NT, Sogaard P, Larsson HBW, **Gøtze JP**, Jøns C, Mogelvang R, Nielsen OW, Fritz-Hansen T. Prediction of progressive left ventricular dilatation and development of symptoms in asymptomatic chronic aortic regurgitation with speckle tracking echocardiography.
4. Rasmussen KC, Højskov M, Thind P, Ruhnau B, Pedersen T, **Gøtze JP**, Secher NH. Pro-atrial natriuretic peptide (proANP) concentrations in plasma is associated with bleeding in major surgery.
5. Harutyunyan MJ, Mathiasen AB, Winkel P, **Gøtze JP**, Fisher-Hansen J, Hildebrandt PR, Jensen GB, Hilden J, Jespersen CM, Kjøller E, Kolmos HJ, Gluud C, Kastrup J. High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: A prognostic study within the CLARICOR trial.
6. Nielsen SJ, Asferg CL, Andersen UB, Linneberg A, Jøns C, **Gøtze JP**, Jeppesen J. Abnormal proANP response to an oral glucose challenge in obese men.
7. Eskesen K, Sogaard P, Larsson H, **Gøtze JP**, Fritz-Hansen T, Olsen NT. Determinants of N-terminal pro-B-type natriuretic peptide levels and correlation with outcome in chronic aortic regurgitation.
8. Christensen HM, Kistorp C, Schou M, Keller N, Frystyk J, Flyvbjerg A, **Gøtze JP**, Faber J. Ongoing muscle wasting despite stable weight in cachectic heart failure patients: A prospective study.
9. Cetti RH, Nielsen JE, Jørgensen A, Grønkær B, **Gøtze JP**, Jørgensen N. Cholesterol in human seminal fluid associated with semen quality.
10. Asferg CL, Andersen UB, Linneberg A, Hedley PL, Chrisitansen M, **Gøtze JP**, Esler M, Jeppesen J. Neuroendocrine markers associated with 24 hour ambulatory blood pressure in obese men.
11. Ambrus RB, Strandby RB, Achiam M, **Gøtze JP**, Fukuoma D, Secher N, Svendsen LB. Plasma atrial natriuretic peptide during abdominal surgery: A systematic review.
12. Valeur N, Ersboll M, Sogaard P, Hassager C, **Gøtze JP**, Kober L. Chromogranin A concentrations are associated with prognosis but not left ventricular systolic function in patients with myocardial infarction.
13. Rasmussen KC, Højskov M, Thind P, Ruhnau B, Sennels HP, Pedersen T, **Gøtze JP**, Secher NH. The stress response is attenuated during robot assisted radical cystectomy.
14. Zaar M, Petersen LG, Rokamp KZ, **Gøtze JP**, Johansson PI, Nielsen RV, Staalsø JM, Olsen NV, Nielsen HB, Secher NH. Effect of Arg16Gly  $\alpha$ 1-adrenergic receptor polymorphism on the hemostatic response to epinephrine in humans.
15. Christensen DL, Espino D, Infante-Ramirez R, Cervantes-Borunda MS, Gernandez-Torres RP, Rivera-Cisneros AE, Castillo D, Westgate K, Terzic D, Brage S, Hassager C, **Gøtze JP**, Kjærgaard J. Exercise-induced cardiac and kidney dysfunctions following ultra-distance running at an altitude variation of 1800 meters in accustomed athletes.
16. Christensen HM, Schou M, **Gøtze JP**, Faber J, Frystyk J, Flyvbjerg A, Hildebrandt P, Kistorp C. Body mass index in chronic heart failure: Association to biomarkers of increased neurohormonal activation, inflammation and adipocytes.
17. Goharian TS, Gimsing AN, **Gøtze JP**, Faber J, Andersen LB, Grøntved A, Jeppesen JL. Tanner stage, serum mid-regional pro-atrial natriuretic peptide and blood pressure in adolescents: effect of gender.
18. Darkner S, **Gøtze JP**, Chen X, Henningsen K, Pehrson S, Svendsen JH. Natriuretic propeptides as markers of atrial fibrillation burden and recurrence: Insights from the AMIO-CAT trial.
19. Jensen KOF, Hansen SH, **Gøtze JP**, Jesting A, Stensballe J, Hansen H. Measurement of apixapan and rivaroxapan in spiked plasma from bleeding patients.

20. Langkilde A, Tavenier J, Andersen O, Johansen IS, **Gøtze JP**, Eugen-Olsen J, Petersen J, Jeppesen J. Midregional proANP concentrations in HIV-infected patients: Associations with body composition, metabolism, and blood pressure.
21. Falkentoft AC, Rørth R, Iversen K, Høfsten DE, Kelbæk H, Holmvang L, Frydland M, Schoos M, Helqvist S, Axelsson A, Clemmensen P, Torp-Pedersen C, Kofoed K, **Gøtze JP**, Engstrøm T, Køber L. Mid-regional Proadrenomedullin - a Prognostic Marker of Mortality and Heart Failure in Patients with ST-Segment Elevation Myocardial Infarction.
22. Busk TM, Bendtsen F, Poulsen JH, Clemmesen JO, Larsen FS, **Gøtze JP**, Iversen JS, Jensen MT, Møgelvang R, Pedersen EB, Bech JN, Møller S. Transjugular intrahepatic portosystemic shunt: Impact on systemic haemodynamics and renal and cardiac function in patients with cirrhosis.
23. Frydland M, Møller JE, Wiberg S, Lindholm MG, Hansen R, Henriques JS, Helgestad-Møller OK, Bang LE, **Gøtze JP**, Thomsen JH, Ouweneel, Obling L, Ravn HB, Holmvang L, Jensen LO, Kjærgaard J, Hassager C. Lactic acid measurement adds prognostic information on 30-day mortality to variables defining cardiogenic shock in patients presenting with STEMI.
24. Arnadóttir A, Vestergaard KR, Pallisgaard J, Soletormos G, Steffensen R, **Gøtze JP**, Iversen K. High-sensitivity troponin T is superior to troponin I in the prediction of mortality in patients without acute coronary syndrome.